Status:
TERMINATED
Endothelial Hyperpolarization in Humans
Lead Sponsor:
Emory University
Collaborating Sponsors:
National Heart, Lung, and Blood Institute (NHLBI)
Conditions:
Hyperlipidemia
Eligibility:
All Genders
21-65 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to elucidate the role Endothelium-Derived Hyperpolarizing Factor (EDHF) plays in dilating blood vessels and whether it differs between healthy people and those with high c...
Detailed Description
The vascular endothelium synthesizes at least four potent vasodilator substances: nitric oxide (NO), prostacyclin, carbon monoxide and endothelium-derived hyperpolarizing factor (EDHF) that contribute...
Eligibility Criteria
Inclusion
- Hyperlipidemic (LDL \> 140)
- Healthy Volunteer
Exclusion
- Pregnancy
- Diabetes mellitus
- Cardiovascular Disease
- Hypertension
- Use of any regular medications
- Renal insufficiency
- Smoking (current or within the past 5 years)
- Bleeding disorder
Key Trial Info
Start Date :
July 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2013
Estimated Enrollment :
174 Patients enrolled
Trial Details
Trial ID
NCT00166166
Start Date
July 1 2002
End Date
January 1 2013
Last Update
August 15 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Emory University School of Medicine
Atlanta, Georgia, United States, 30322